These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 24656175)

  • 21. Reduced neutralizing antibody titer against genotype I virus in swine immunized with a live-attenuated genotype III Japanese encephalitis virus vaccine.
    Fan YC; Chen JM; Chen YY; Lin JW; Chiou SS
    Vet Microbiol; 2013 May; 163(3-4):248-56. PubMed ID: 23415032
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protection of swine by potent neutralizing anti-Japanese encephalitis virus monoclonal antibodies derived from vaccination.
    Young CL; Lyons AC; Hsu WW; Vanlandingham DL; Park SL; Bilyeu AN; Ayers VB; Hettenbach SM; Zelenka AM; Cool KR; Peterson GJ; Higgs S; Huang YS
    Antiviral Res; 2020 Feb; 174():104675. PubMed ID: 31825852
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.
    Monath TP; Guirakhoo F; Nichols R; Yoksan S; Schrader R; Murphy C; Blum P; Woodward S; McCarthy K; Mathis D; Johnson C; Bedford P
    J Infect Dis; 2003 Oct; 188(8):1213-30. PubMed ID: 14551893
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Single-dose, live-attenuated Japanese encephalitis vaccine in children aged 12-18 months: randomized, controlled phase 3 immunogenicity and safety trial.
    Feroldi E; Pancharoen C; Kosalaraksa P; Watanaveeradej V; Phirangkul K; Capeding MR; Boaz M; Gailhardou S; Bouckenooghe A
    Hum Vaccin Immunother; 2012 Jul; 8(7):929-37. PubMed ID: 22777096
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cellular Immune Responses to Live Attenuated Japanese Encephalitis (JE) Vaccine SA14-14-2 in Adults in a JE/Dengue Co-Endemic Area.
    Turtle L; Tatullo F; Bali T; Ravi V; Soni M; Chan S; Chib S; Venkataswamy MM; Fadnis P; Yaïch M; Fernandez S; Klenerman P; Satchidanandam V; Solomon T
    PLoS Negl Trop Dis; 2017 Jan; 11(1):e0005263. PubMed ID: 28135273
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and immunogenicity of a freeze-dried, Vero cell culture-derived, inactivated Japanese encephalitis vaccine (KD-287, ENCEVAC®) versus a mouse brain-derived inactivated Japanese encephalitis vaccine in children: a phase III, multicenter, double-blinded, randomized trial.
    Yun KW; Lee HJ; Kang JH; Eun BW; Kim YJ; Kim KH; Kim NH; Hong YJ; Kim DH; Kim HM; Cha SH
    BMC Infect Dis; 2015 Jan; 15():7. PubMed ID: 25567119
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Persistence of antibodies six years after booster vaccination with inactivated vaccine against Japanese encephalitis.
    Paulke-Korinek M; Kollaritsch H; Kundi M; Zwazl I; Seidl-Friedrich C; Jelinek T
    Vaccine; 2015 Jul; 33(30):3600-4. PubMed ID: 26036947
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine: randomized double-blind phase II evaluation of safety and immunogenicity.
    Nasveld PE; Marjason J; Bennett S; Aaskov J; Elliott S; McCarthy K; Kanesa-Thasan N; Feroldi E; Reid M
    Hum Vaccin; 2010 Nov; 6(11):906-14. PubMed ID: 20864814
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genotype-specific neutralization determinants in envelope protein: implications for the improvement of Japanese encephalitis vaccine.
    Ye Q; Xu YP; Zhang Y; Li XF; Wang HJ; Liu ZY; Li SH; Liu L; Zhao H; Nian QG; Deng YQ; Qin ED; Qin CF
    J Gen Virol; 2015 Aug; 96(8):2165-2175. PubMed ID: 25908779
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term follow-up of Japanese encephalitis chimeric virus vaccine: Immune responses in children.
    Chokephaibulkit K; Sirivichayakul C; Thisyakorn U; Pancharoen C; Boaz M; Bouckenooghe A; Feroldi E
    Vaccine; 2016 Nov; 34(46):5664-5669. PubMed ID: 27686833
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Japanese encephalitis protein vaccine candidates expressing neutralizing epitope and M.T hsp70 induce virus-specific memory B cells and long-lasting antibodies in swine.
    Fei-fei G; Jian W; Feng X; Li-ping S; Quan-yun S; Jin-ping Z; Pu-yan C; Pei-hong L
    Vaccine; 2008 Oct; 26(44):5590-4. PubMed ID: 18761388
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term immunogenicity of the SA14-14-2 Japanese encephalitis (JE) vaccine (CD.JEVAX®) booster following chimeric JE (IMOJEV®) vaccine priming in Thai children.
    Chotpitayasunondh T; Suntarattiwong P; Yoksan S
    Hum Vaccin Immunother; 2024 Dec; 20(1):2407663. PubMed ID: 39353860
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Partial cross-protection between Japanese encephalitis virus genotype I and III in mice.
    Wei J; Wang X; Zhang J; Guo S; Pang L; Shi K; Liu K; Shao D; Qiu Y; Liu L; Widén F; Li B; Ma Z
    PLoS Negl Trop Dis; 2019 Aug; 13(8):e0007601. PubMed ID: 31374086
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of serological diagnostic test systems assessing the immune response to Japanese encephalitis vaccination.
    Litzba N; Klade CS; Lederer S; Niedrig M
    PLoS Negl Trop Dis; 2010 Nov; 4(11):e883. PubMed ID: 21103412
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Persistence of IgM Antibodies after Vaccination with Live Attenuated Japanese Encephalitis Vaccine.
    Hills SL; Van Keulen A; Feser J; Panella A; Letson GW; Staples JE; Marfin AA; Brault AC
    Am J Trop Med Hyg; 2020 Nov; 104(2):576-579. PubMed ID: 33236716
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Electroporation enhances protective immune response of a DNA vaccine against Japanese encephalitis in mice and pigs.
    Sheng Z; Gao N; Cui X; Fan D; Chen H; Wu N; Wei J; An J
    Vaccine; 2016 Nov; 34(47):5751-5757. PubMed ID: 27743649
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of genomic variation in the challenge virus on the neutralization titres of recipients of inactivated JE vaccines--report of a collaborative study on PRNT50 assays for Japanese encephalitis virus (JE) antibodies.
    Ferguson M; Johnes S; Li L; Heath A; Barrett A
    Biologicals; 2008 Mar; 36(2):111-6. PubMed ID: 17892945
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunogenicity and Safety of a Booster Dose of a Live Attenuated Japanese Encephalitis Chimeric Vaccine Given 1 Year After Primary Immunization in Healthy Children in the Republic of Korea.
    Kim DS; Jang GC; Cha SH; Choi SH; Kim HM; Kim JH; Kang JH; Kim JH; Kim KH; Bang J; Naimi Z; Bouckenooghe A; Bosch-Castells V; Houillon G
    Pediatr Infect Dis J; 2016 Feb; 35(2):e60-4. PubMed ID: 26535878
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protection of SA14-14-2 live attenuated Japanese encephalitis vaccine against the wild-type JE viruses.
    Jia L; Wang Z; Yu Y
    Chin Med J (Engl); 2003 Jun; 116(6):941-3. PubMed ID: 12877812
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modeling the long-term persistence of neutralizing antibody in children and toddlers after vaccination with live attenuated Japanese encephalitis chimeric virus vaccine.
    Bouckenooghe A; Bailleux F; Feroldi E
    Hum Vaccin Immunother; 2019; 15(1):72-79. PubMed ID: 30230947
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.